Roche continues to ramp up investment in China

Global pharmaceutical giant Roche declared a strengthened commitment to the Chinese market at the recent 30th anniversary celebration of Roche Pharmaceuticals China in Shanghai.

This celebratory event marks a new chapter in Roche's development in China, with the company pledging to accelerate the development of more innovative drugs originating from China, further localize production and upgrade investments.

The company aims to perfect a complete end-to-end pharmaceutical value industrial chain covering early-stage research and development, drug development, production, open collaboration, and commercial operations to better serve Chinese patients.

Its innovative flu drug Xofluza is expected to achieve localized production in Shanghai's Pudong New Area by 2024.

Since Roche established a presence in Pudong in 1994, the multinational company has been dedicated to providing differentiated medications and innovative solutions for Chinese patients.

Currently, Roche boasts 28 products across eight major therapeutic areas in China. The Roche China Innovation Center, one of the first foreign-funded research and development centers in China, holds independent decision-making power in new drug research and early-stage development, continuously developing innovative drugs for patients. The Roche China Accelerator fosters local innovation, accelerating the transformation of research outcomes into commercial products and helping Chinese innovation to reach global markets.

In the field of biopharmaceuticals, Pudong is accelerating efforts to promote innovative reforms such as foreign access to diagnostic technologies, segmented cross-border production of biological products, and rapid entry of innovative medical devices into hospitals. These reforms aim to create a more competitive, market-oriented, law-based, and internationalized business environment, advancing toward the goal of forging a world-class biopharmaceutical industrial cluster.